BICKI
DEAD

Serial Number

88103626

Owner

OSE Immunotherapeutics

Attorney

Patrick J. Jennings

Filing Date

Sep 4, 2018

Add to watchlist:

No watchlists yet
View on USPTO

BICKI Trademark

Serial Number: 88103626 • Registration: 5855074

BICKI is a trademark filed by OSE Immunotherapeutics on September 4, 2018. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

OSE Immunotherapeutics

22 Boulevard Benoni Goullin
Nantes 44200 , FR

Entity Type: 99

Trademark Details

Filing Date

September 4, 2018

Registration Date

September 10, 2019

Published for Opposition

February 5, 2019

Cancellation Date

March 20, 2026

Goods & Services

(Based on 44(e)) Scientific and technological services, namely, research and design in the field of medicine and health; Design and development of software and data bases; Medical research; Research relating to biology and biotechnology; Pharmaceutical research services; Clinical research in the field of cancer and autoimmune diseases; Research and development services in the field of immunology; research and development in the field of microorganisms, cells and antibodies; Research and development of vaccines and medicines; biological analysis; Biological laboratory services; Advice on research and development in the field of therapeutics; Laboratory services relating to the production of monoclonal antibodies; Research and development services in the field of antibodies

(Based on 44(e)) Provision of medical services; Advice relating to immunology; Therapy services in the nature of therapeutic health care services

(Based on 44(e)) Pharmaceuticals for the treatment of cancer and autoimmune diseases; Sanitary preparations for medical purposes; Dietetic foods and beverages adapted for medical use; Medicines for human purposes, namely, medicines for treating cancer and autoimmune diseases; Chemical preparations for medical or pharmaceutical purposes, namely, treating cancer and autoimmune diseases; Vaccines; Serums; Chemical reagents for medical use; Disinfectants; Pharmaceutical preparations for the treatment of autoimmune diseases; Immunostimulants; Immunomodulators; Immunoassay reagents for medical use; Biological preparations for the treatment of cancer; Biological preparations for the treatment of cancer and autoimmune diseases; Monoclonal antibodies for use in disease testing

Filing History

CANCELLED SEC. 8 (6-YR)
Mar 20, 2026 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Sep 10, 2024 REM1
REGISTERED-PRINCIPAL REGISTER
Sep 10, 2019 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Aug 7, 2019 DP1B
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Aug 7, 2019 AITU
NOTICE OF ALLOWANCE CANCELLED
Jul 18, 2019 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
Jul 18, 2019 D1BR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 2, 2019 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 5, 2019 NPUB
PUBLISHED FOR OPPOSITION
Feb 5, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 16, 2019 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 28, 2018 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 28, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 28, 2018 CRFA
ASSIGNED TO LIE
Dec 27, 2018 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 20, 2018 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 15, 2018 GNRN
NON-FINAL ACTION E-MAILED
Dec 15, 2018 GNRT
NON-FINAL ACTION WRITTEN
Dec 15, 2018 CNRT
ASSIGNED TO EXAMINER
Dec 14, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 11, 2018 NWOS
NEW APPLICATION ENTERED
Sep 7, 2018 NWAP